Alessandra Silva

Mrs. Alessandra Silva


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Bruno Amorim-CarmoBruno Amorim-Carmo
Bruno Amorim-Carmo
ASAlessandra Silva
Alessandra Silva
APAdriana Parente
Adriana Parente
AFAllanny A. Furtado
Allanny A. Furtado
ECEneas Carvalho
Eneas Carvalho
MPMatheus Pedrosa
Matheus Pedrosa
Scorpion venom constitutes a rich source of biologically active compounds with high potential for therapeutic and biotechnological applications that can be used as prototypes for the design of new drugs. The aim of this study was to characterize the structural conformation, evaluate the antimicrobial activity, and gain insight into the possible action mechanism underlying it, for two new analog peptides of the scorpion peptide Stigmurin, named StigA25 and StigA31. The amino acid substitutions in the native sequence for lysine residues resulted in peptides with higher positive net charge and hydrophobicity, with an increase in the theoretical helical content. StigA25 and StigA31 showed the capacity to modify their structural conformation according to the environment, and were stable to pH and temperature variation—results similar to the native peptide. Both analog peptides demonstrated broad-spectrum antimicrobial activity in vitro, showing an effect superior to that of the native peptide, being non-hemolytic at the biologically active concentrations. Therefore, this study demonstrates the therapeutic potential of the analog peptides from Stigmurin and the promising approach of rational drug design based on scorpion venom peptide to obtain new anti-infective agents.


18 April 2018 in Toxins
Verified
Journal Article
Open access
PDF file
APAdriana Parente
Adriana Parente
ASAlessandra Silva
Alessandra Silva
AFAllanny A. Furtado
Allanny A. Furtado
MMMenilla A. Melo
Menilla A. Melo
ALAriane Lacerda
Ariane Lacerda
MPMatheus Pedrosa
Matheus Pedrosa
Scorpion venom is a rich source of biologically active components and various peptides with high-potential therapeutic use that have been characterized for their antimicrobial and antiproliferative activities. Stigmurin is a peptide identified from the Tityus stigmurus venom gland with high antibacterial and antiproliferative activities and low toxicity. Amino acid substitutions in peptides without a disulfide bridge sequence have been made with the aim of reducing their toxicity and increasing their biological activities. The purpose of this study was to evaluate the structural conformation and structural stability, as well as antimicrobial, antiproliferative, and hemolytic activities of two peptide analogs to Stigmurin, denominated StigA6 and StigA16. In silico analysis revealed the α-helix structure for both analog peptides, which was confirmed by circular dichroism. Data showed that the net charge and hydrophobic moment of the analog peptides were higher than those for Stigmurin, which can explain the increase in antimicrobial activity presented by them. Both analog peptides exhibited activity on cancerous cells similar to the native peptide; however, they were less toxic when tested on the normal cell line. These results reveal a potential biotechnological application of the analog peptides StigA6 and StigA16 as prototypes to new therapeutic agents.

1 October 2016 in Toxicon
Verified
Journal Article
Closed access
ASAlessandra Silva
Alessandra Silva
RMRichele J.A. Machado
Richele J.A. Machado
NMNorberto K.V. Monteiro
Norberto K.V. Monteiro
AEAndréia B. Estrela
Andréia B. Estrela
ESElizabeth Santos
Elizabeth Santos
MPMatheus Pedrosa
Matheus Pedrosa

12 February 2021 in Marine Drugs
Verified
Journal Article
Open access
PDF file
NSNayara Sousa da Silva
Nayara Sousa da Silva
NANathalia Araujo
Nathalia Araujo
ASAlessandra Silva
Alessandra Silva
JOJohny Olivera
Johny Olivera
JDJulia M M Dantas
Julia M M Dantas
MPMatheus Pedrosa
Matheus Pedrosa
The global rise of infectious disease outbreaks and the progression of microbial resistance reinforce the importance of researching new biomolecules. Obtained from the hydrolysis of chitosan, chitooligosaccharides (COSs) have demonstrated several biological properties, including antimicrobial, and greater advantage over chitosan due to their higher solubility and lower viscosity. Despite the evidence of the biotechnological potential of COSs, their effects on trypanosomatids are still scarce. The objectives of this study were the enzymatic production, characterization, and in vitro evaluation of the cytotoxic, antibacterial, antifungal, and antiparasitic effects of COSs. NMR and mass spectrometry analyses indicated the presence of a mixture with 81% deacetylated COS and acetylated hexamers. COSs demonstrated no evidence of cytotoxicity upon 2 mg/mL. In addition, COSs showed interesting activity against bacteria and yeasts and a time-dependent parasitic inhibition. Scanning electron microscopy images indicated a parasite aggregation ability of COSs. Thus, the broad biological effect of COSs makes them a promising molecule for the biomedical industry.

16 April 2018 in Toxins
Verified
Journal Article
Open access
PDF file
KSKarla Samara Rocha Soares
Karla Samara Rocha Soares
FGFiamma Gláucia-Silva
Fiamma Gláucia-Silva
ASAlessandra Silva
Alessandra Silva
MTManoela Torres-Rêgo
Manoela Torres-Rêgo
NANathalia Araujo
Nathalia Araujo
MPMatheus Pedrosa
Matheus Pedrosa
In Brazil, envenomation by snakes of the genus Bothrops is clinically relevant, particularly for the species Bothrops jararaca and B. erythromelas. The most effective treatment for envenomation by snakes is the administration of antivenoms associated with adjuvants. Novel adjuvants are required to reduce side effects and maximize the efficiency of conventional serum and vaccine formulations. The polymer chitosan has been shown to have immunoadjuvant properties, and it has been used as a platform for delivery systems. In this context, we evaluated the potential immunoadjuvant properties of chitosan nanoparticles (CNPs) loaded with B. jararaca and B. erythromelas venoms in the production of sera against these venoms. Stable CNPs were obtained by ionic gelation, and mice were immunized subcutaneously for 6 weeks with 100 µL of each snake venom at concentrations of 5.0 or 10.0% (w/w), encapsulated in CNPs or associated with aluminium hydroxide (AH). The evaluation of protein interactions with the CNPs revealed their ability to induce antibody levels equivalent to those of AH, even with smaller doses of antigen. In addition, the CNPs were less inflammatory due to their modified release of proteins. CNPs provide a promising approach for peptide/protein delivery from snake venom and will be useful for new vaccines.